B-Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy Alleviated Heart Failure in Patients with Multiple Myeloma

作者：Yun-Hong Wang, Ke Zhang, Xiaohui Suo, Ning Meng, Yuanrui Gu, Yilang Qin, Yanxia Tu, Xiaohui Zhang, Guofeng Sun, Jiaojiao Ji, Weichun Wu, Yuqi Cai, Kai Yang, Chenxi Ouyang, Junyuan Qi · 发表于：ESC Heart Failure · 年份：2023 · DOI：10.1002/ehf2.14554 · 被引用次数：6 · 研究领域：Signaling Pathways in Disease、Multiple Myeloma Research and Treatments、Amyloidosis: Diagnosis, Treatment, Outcomes

Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved. We produced anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells, which are in a trial for patients with relapsed/refractory MM. One enrolled patient developed severe heart failure, highly suspected as light chain cardiac amyloidosis. He exhibited increased N-terminal pro-brain natriuretic peptide with a peak of 32 299 ng/mL and heart failure with an ejection fraction of 30%. Anti-BCMA CAR-T cells were administered following lymphodepletion. The patient achieved cardiac response within 1 week with a decrease in N-terminal pro-brain natriuretic peptide by 80%, an increase in ejection fraction from 30% to 56%, and a haematological response with negative minimal residual disease at 1 month and a complete response at 1 year. To date, this patient has maintained good health without heart failure or haematological relapse. Herein, we show the efficacy of anti-BCMA CAR-T cells in patients with MM and severe heart failure.